Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumors
MET Gene Alterations

Interventions

DRUG: elzovantinib (TPX-0022)

Sponsor

Turning Point Therapeutics, Inc.